Cancer imposes enormous financial burden to society. Direct medical costs were estimated at around €51 billion across European (EU) countries (2009) and $88.7 billion in the United-States (US) (2011). The concept of “financial toxicity” has been first reported by US academic oncologists, Zafar and Abernathy in 2013. It refers to financial distress linked to out-of-pocket payments of costly oncology drugs (OD). This critical concept led to the development of a patient-reported outcome questionnaire by de Souza et al.